Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $19000.0.

  • Compass Therapeutics' Depreciation & Amortization (CF) fell 8671.33% to $19000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $399000.0, marking a year-over-year decrease of 3459.02%. This contributed to the annual value of $589000.0 for FY2024, which is 1573.68% down from last year.
  • Per Compass Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $19000.0 for Q3 2025, which was down 8671.33% from $100000.0 recorded in Q2 2025.
  • Compass Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $194000.0 for Q1 2023, and its period low was $19000.0 during Q3 2025.
  • For the 3-year period, Compass Therapeutics' Depreciation & Amortization (CF) averaged around $140636.4, with its median value being $152000.0 (2024).
  • Over the last 5 years, Compass Therapeutics' Depreciation & Amortization (CF) had its largest YoY gain of 909.09% in 2025, and its largest YoY loss of 8671.33% in 2025.
  • Compass Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $161000.0 in 2023, then fell by 13.04% to $140000.0 in 2024, then plummeted by 86.43% to $19000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $19000.0 in Q3 2025, compared to $100000.0 in Q2 2025 and $140000.0 in Q1 2025.